[HONG KONG, April 6, 2022] Recently, Microsoft Accelerator officially announced the “2022 Spring Semester List” and Great Bay Bio (GBB) was successfully listed on the “medical and lifescience” group.

After GBB joined the “Spring Semester of Microsoft Acceleration Program”, Microsoft accelerator will provide support intechnology, customers, mentors, market, investment and other aspects toaccelerate GBB to build a new generation of AI drug R&D of ecological system, and solve many pain points such as low success rate, long cycle, and high cost.

About Spring Semester of Microsoft Acceleration Program

The spring semester of Microsoft acceleration program was launched on January 11, 2022. After several rounds of screening and striction by a jury composed of Microsoft industry experts, VC partners and external industry experts, a total of 28 enterprises were selected. Microsoft accelerator will helped enterprises grow rapidly in terms of technology, customers, mentors, market, investment resources, etc.

The enterprises selected in the 2022 spring semester cover medical, industrial, cultural and entertainment, cross industry enterprise services and other fields, of which two-thirds have a total financing amount of more than RMB 100 million, with a total valuation of nearly RMB 30 billion.